Brought to you by 
SmithKline and Alizyme partner for renzapride development
Aug 1998
Executive Summary
Alizyme, a biotech specializing in obesity and gastrointestinal therapeutics, will codevelop and has optioned rights to SmithKline's renzapride compound and its derivatives.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Reverse Licensing
- R+D and Marketing-Licensing
- Includes Equity
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SmithKline and Alizyme partner for renzapride development
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice